Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. (the "Company") on July 21, 2020. The filing details significant corporate governance changes and officer appointments mandated by a court-approved settlement agreement regarding a consolidated shareholder derivative action (Case No. 2:18-cv-15992).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance, legal compliance, and personnel changes rather than financial performance.
Material Changes
- Officer Appointment: Christopher C. Schreiber, previously Executive Chairman, was appointed President of the Company on July 21, 2020. His existing employment agreement remains in effect.
- Bylaw Amendments: The Board adopted Amended and Restated Bylaws effective July 21, 2020, to comply with the settlement order. Key provisions include:
- Requirement for Board members to attend annual shareholder meetings in person.
- Rotation of the Chairman of the Board role among independent directors every five years.
- Mandatory composition of at least 50% independent directors.
- Requirement for independent directors to meet in executive session at least four times per year.
- Mandatory separation of the Chairman and CEO roles after November 27, 2020.
- Prohibition on one individual serving as both CEO and CFO after November 27, 2020.
- Committee and Policy Revisions:
- Establishment of a new Risk and Disclosure Committee, with members drawn from the Audit Committee.
- Adoption of a new Whistleblower Policy.
- Revisions to the Code of Ethics to align with new policies and clarify enforcement mechanisms.
- Revised charters for the Audit, Nominating and Corporate Governance, and Compensation Committees to enhance oversight of internal controls, legal compliance, and executive compensation.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or operational outlook. The primary risk context is the ongoing compliance with the court order from the shareholder derivative action, which requires these governance changes to remain in place for at least four years. The new Risk and Disclosure Committee is tasked with monitoring compliance with the Code of Ethics and addressing whistleblower complaints.
Key Facts for Investor Verification
- Verify the timeline for the mandatory separation of the CEO and Chairman roles (post-November 27, 2020).
- Confirm the composition of the Board to ensure it meets the 50% independent director requirement.
- Review the attached exhibits (Amended Bylaws, Code of Ethics, Committee Charters) for specific operational constraints.
- Monitor future filings for the appointment of a new CEO distinct from the Chairman, as required by the settlement.